Search

Your search keyword '"Coupé, Veerle M. H."' showing total 405 results
Start Over Author "Coupé, Veerle M. H." Search Limiters Academic (Peer-Reviewed) Journals
405 results on '"Coupé, Veerle M. H."'

3. A Bayesian accelerated failure time model for interval censored three-state screening outcomes

Author

Klausch, Thomas, Akwiwu, Eddymurphy U., van de Wiel, Mark A., Coupe, Veerle M. H., and Berkhof, Johannes

Subjects
Statistics - Methodology, 62N02
Abstract

Women infected by the Human papilloma virus are at an increased risk to develop cervical intraepithalial neoplasia lesions (CIN). CIN are classified into three grades of increasing severity (CIN-1, CIN-2, and CIN-3) and can eventually develop into cervical cancer. The main purpose of screening is detecting CIN-2 and CIN-3 cases which are usually surgically removed. Screening data from the POBASCAM trial involving 1,454 HPV-positive women is analyzed with two objectives: estimate (a) the transition time from HPV diagnosis to CIN-3; and (b) the transition time from CIN-2 to CIN-3. The screening data have two key characteristics. First, the CIN state is monitored in an interval-censored sequence of screening times. Second, a woman's progression to CIN-3 is only observed, if the woman progresses to, both, CIN-2 and from CIN-2 to CIN-3 in the same screening interval. We propose a Bayesian accelerated failure time model for the two transition times in this three-state model. To deal with the unusual censoring structure of the screening data, we develop a Metropolis-within-Gibbs algorithm with data augmentation from the truncated transition time distributions., Comment: 22 pages (Manuscript), 34 pages (Supplemental Material)

Published
2021

4. Towards patient-led follow-up after curative surgical resection of stage I, II and III colorectal cancer (DISTANCE-trial): a study protocol for a stepped-wedge cluster-randomised trial

Author

Swartjes, Hidde, Qaderi, Seyed M., Teerenstra, Steven, Custers, Jose A. E., Elferink, Marloes A. G., van Wely, Bob J., Burger, Jacobus W. A., van Grevenstein, Wilhelmina M. U., van Duijvendijk, Peter, Verdaasdonk, Emiel G. G., de Roos, Marnix A. J., Coupé, Veerle M. H., Vink, Geraldine R., Verhoef, Cornelis, and de Wilt, Johannes H. W.

Published
2023
Full Text
View/download PDF

6. The multitarget faecal immunochemical test for improving stool-based colorectal cancer screening programmes: a Dutch population-based, paired-design, intervention study

Author

Wisse, Pieter H A, de Klaver, Willemijn, van Wifferen, Francine, van Maaren-Meijer, Frejanne G, van Ingen, Huub E, Meiqari, Lana, Huitink, Iris, Bierkens, Mariska, Lemmens, Margriet, Greuter, Marjolein J E, van Leerdam, Monique E, Spaander, Manon C W, Dekker, Evelien, Coupé, Veerle M H, Carvalho, Beatriz, de Wit, Meike, and Meijer, Gerrit A

Published
2024
Full Text
View/download PDF

8. Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer.

Author

Kramer, Astrid, Greuter, Marjolein J. E., Schraa, Suzanna J., Vink, Geraldine R., Phallen, Jillian, Velculescu, Victor E., Meijer, Gerrit A., van den Broek, Daan, Koopman, Miriam, Roodhart, Jeanine M. L., Fijneman, Remond J. A., Retèl, Valesca P., and Coupé, Veerle M. H.

Abstract

Background: Current patient selection for adjuvant chemotherapy (ACT) after curative surgery for stage II colon cancer (CC) is suboptimal, causing overtreatment of high-risk patients and undertreatment of low-risk patients. Postoperative circulating tumor DNA (ctDNA) could improve patient selection for ACT. Objectives: We conducted an early model-based evaluation of the (cost-)effectiveness of ctDNA-guided selection for ACT in stage II CC in the Netherlands to assess the conditions for cost-effective implementation. Methods: A validated Markov model, simulating 1000 stage II CC patients from diagnosis to death, was supplemented with ctDNA data. Five ACT selection strategies were evaluated: the current guideline (pT4, pMMR), ctDNA-only, and three strategies that combined ctDNA status with pT4 and pMMR status in different ways. For each strategy, the costs, life years, quality-adjusted life years (QALYs), recurrences, and CC deaths were estimated. Sensitivity analyses were performed to assess the impact of the costs of ctDNA testing, strategy adherence, ctDNA as a predictive biomarker, and ctDNA test performance. Results: Model predictions showed that compared to current guidelines, the ctDNA-only strategy was less effective (+2.2% recurrences, −0.016 QALYs), while the combination strategies were more effective (−3.6% recurrences, +0.038 QALYs). The combination strategies were not cost-effective, since the incremental cost-effectiveness ratio was €67,413 per QALY, exceeding the willingness-to-pay threshold of €50,000 per QALY. Sensitivity analyses showed that the combination strategies would be cost-effective if the ctDNA test costs were lower than €1500, or if ctDNA status was predictive of treatment response, or if the ctDNA test performance improved substantially. Conclusion: Adding ctDNA to current high-risk clinicopathological features (pT4 and pMMR) can improve patient selection for ACT and can also potentially be cost-effective. Future studies should investigate the predictive value of post-surgery ctDNA status to accurately evaluate the cost-effectiveness of ctDNA testing for ACT decisions in stage II CC. Plain language summary: Effectiveness and cost-effectiveness of circulating tumour DNA-guided selection for adjuvant chemotherapy in patients with stage II colon cancer Most patients with stage II colon cancer (CC) are cured by surgery. Therefore, guidelines recommend to only offer adjuvant chemotherapy to patients who have a tumor with high-risk features. However, current selection is suboptimal, leading to recurrence of cancer in 13% of low-risk patients and unnecessary administration of chemotherapy in some high-risk patients. Previous studies indicate that a biomarker, so-called circulating tumour DNA (ctDNA), could improve the selection of high-risk patients for adjuvant chemotherapy, as patients who have detectable ctDNA in their blood after surgery are likely to develop a recurrence. Despite its potential, implementation is still pending. Our study assessed the long-term effectiveness and costs associated with various ctDNA-guided strategies for selecting high-risk patients for adjuvant chemotherapy in stage II CC. We used an health-economic model to simulate a cohort of 1000 Dutch patients with stage II CC from diagnosis to death. Next, we compared the health outcomes and costs of the ctDNA-guided strategies to those when selection is based on the Dutch guideline. We found that a combination of the Dutch guideline and ctDNA was the most effective strategy, but not cost-effective. Additional analyses showed that ctDNA-guided selection were cost-effective if the costs of the ctDNA test were below 1500 euros, if the ctDNA test performed significantly better, or if patients with detectable ctDNA responded better to chemotherapy. Thus, while post-surgery ctDNA status is a good indicator for recurrence risk, specific criteria related to ctDNA test performance and costs, in addition to combining ctDNA with current high-risk features, should be met to achieve cost-effective implementation. Looking ahead, future studies should explore how patients with detectable ctDNA respond to chemotherapy for next assessments of the cost-effectiveness of ctDNA-guided strategies in selecting patients with stage II CC for adjuvant chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Benefit-Harm Analysis for Informed Decision Making on Participating in Colorectal Cancer Screening: A Modeling Study

Author

Yebyo, Henock G; https://orcid.org/0000-0001-5400-2448, van Wifferen, Francine, Pluymen, Linda P M, Leeflang, Mariska M G, Dekker, Evelien, Coupé, Veerle M H, Puhan, Milo A; https://orcid.org/0000-0001-7284-1317, Greuter, Marjolein J E, Stegeman, Inge, Yebyo, Henock G; https://orcid.org/0000-0001-5400-2448, van Wifferen, Francine, Pluymen, Linda P M, Leeflang, Mariska M G, Dekker, Evelien, Coupé, Veerle M H, Puhan, Milo A; https://orcid.org/0000-0001-7284-1317, Greuter, Marjolein J E, and Stegeman, Inge

Abstract

OBJECTIVES To facilitate informed decision making on participating in colorectal cancer (CRC) screening, we assessed the benefit-harm balance of CRC screening for a wide range of subgroups over different time horizons. METHODS The study combined incidence proportions of benefits and harms of (not) participating in CRC screening estimated by the Adenoma and Serrated pathway to CAncer microsimulation model, a preference eliciting survey, and benefit-harm balance modeling combining all outcomes to determine the net health benefit of CRC screening over 10, 20, and 30 years. Probability of net health benefit was estimated for 210 different subgroups based on age, sex, previous participation in CRC screening, and lifestyle. RESULTS CRC screening was net beneficial in 183 of 210 subgroups over 30 years (median probability [MP] of 0.79, interquartile range [IQR] of 0.69-0.85) across subgroups. Net health benefit was greater for men (MP 0.82; IQR 0.69-0.89) than women (MP 0.76; IQR 0.67-0.83) and for those without history of participation in previous screenings (MP 0.84; IQR 0.80-0.89) compared with those with (MP 0.69; IQR 0.59-0.75). Net health benefit decreased with increasing age, from MP of 0.84 (IQR 0.80-0.86) at age 55 to 0.61 (IQR 0.56-0.71) at age 75. Shorter time horizons led to lower benefit, with MP of 0.70 (IQR 0.62-0.80) over 20 years and 0.54 (IQR 0.48-0.67) over 10 years. CONCLUSIONS Our benefit-harm analysis provides information about net health benefit of screening participation, based on important characteristics and preferences of individuals, which could assist screening invitees in making informed decisions on screening participation.

Published
2024

13. Benefit-harm analysis for informed decision making on participating in colorectal cancer screening: A Modeling Study

Author

Public Health Epidemiologie, MS KNO, Brain, Yebyo, Henock G, van Wifferen, Francine, Pluymen, Leeflang, Mariska M G, Dekker, Evelien, Coupé, Veerle M H, Puhan, Milo A, Greuter, Marjolein J E, Stegeman, Inge, Public Health Epidemiologie, MS KNO, Brain, Yebyo, Henock G, van Wifferen, Francine, Pluymen, Leeflang, Mariska M G, Dekker, Evelien, Coupé, Veerle M H, Puhan, Milo A, Greuter, Marjolein J E, and Stegeman, Inge

Published
2024

15. An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles

Author

Bresalier, Robert S, primary, Senore, Carlo, additional, Young, Graeme P, additional, Allison, James, additional, Benamouzig, Robert, additional, Benton, Sally, additional, Bossuyt, Patrick M M, additional, Caro, Luis, additional, Carvalho, Beatriz, additional, Chiu, Han-Mo, additional, Coupé, Veerle M H, additional, de Klaver, Willemijn, additional, de Klerk, Clasine Maria, additional, Dekker, Evelien, additional, Dolwani, Sunil, additional, Fraser, Callum G, additional, Grady, William, additional, Guittet, Lydia, additional, Gupta, Samir, additional, Halloran, Stephen P, additional, Haug, Ulrike, additional, Hoff, Geir, additional, Itzkowitz, Steven, additional, Kortlever, Tim, additional, Koulaouzidis, Anastasios, additional, Ladabaum, Uri, additional, Lauby-Secretan, Beatrice, additional, Leja, Mārcis, additional, Levin, Bernard, additional, Levin, Theodore Robert, additional, Macrae, Finlay, additional, Meijer, Gerrit A, additional, Melson, Joshua, additional, O'Morain, Colm, additional, Parry, Susan, additional, Rabeneck, Linda, additional, Ransohoff, David F, additional, Sáenz, Roque, additional, Saito, Hiroshi, additional, Sanduleanu-Dascalescu, Silvia, additional, Schoen, Robert E, additional, Selby, Kevin, additional, Singh, Harminder, additional, Steele, Robert J C, additional, Sung, Joseph J Y, additional, Symonds, Erin Leigh, additional, and Winawer, Sidney J, additional

Published
2023
Full Text
View/download PDF

19. Prevalence of adjustment disorder among cancer patients, and the reach, effectiveness, cost-utility and budget impact of tailored psychological treatment: study protocol of a randomized controlled trial

Author

van Beek, Florie E., Wijnhoven, Lonneke M. A., Jansen, Femke, Custers, José A. E., Aukema, Eline J., Coupé, Veerle M. H., Cuijpers, Pim, van der Lee, Marije L., Lissenberg-Witte, Birgit I., Wijnen, Ben, Prins, Judith B., and Verdonck-de Leeuw, Irma M.

Published
2019
Full Text
View/download PDF

22. Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Mfumbilwa, Zakile A, Wilschut, Janneke A, Simons, Martijn J H G, Ramaekers, Bram, Joore, Manuela, Retèl, Valesca, der Welle, Christine M Cramer-van, Schramel, Franz M N H, van de Garde, Ewoudt M W, Coupé, Veerle M H, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Mfumbilwa, Zakile A, Wilschut, Janneke A, Simons, Martijn J H G, Ramaekers, Bram, Joore, Manuela, Retèl, Valesca, der Welle, Christine M Cramer-van, Schramel, Franz M N H, van de Garde, Ewoudt M W, and Coupé, Veerle M H

Published
2023

23. Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas:A Nested Case-Control Study

Author

Jodal, Henriette C, Akwiwu, Eddymurphy U, Lemmens, Margriet, Delis-van Diemen, Pien M, Klotz, Dagmar, Leon, Leticia G, Lakbir, Soufyan, de Wit, Meike, Fijneman, Remond J A, van Leerdam, Monique E, Dekker, Evelien, Spaander, Manon C W, Meijer, Gerrit A, Løberg, Magnus, Coupé, Veerle M H, Kalager, Mette, Carvalho, Beatriz, Jodal, Henriette C, Akwiwu, Eddymurphy U, Lemmens, Margriet, Delis-van Diemen, Pien M, Klotz, Dagmar, Leon, Leticia G, Lakbir, Soufyan, de Wit, Meike, Fijneman, Remond J A, van Leerdam, Monique E, Dekker, Evelien, Spaander, Manon C W, Meijer, Gerrit A, Løberg, Magnus, Coupé, Veerle M H, Kalager, Mette, and Carvalho, Beatriz

Abstract

UNLABELLED: Current morphologic features defining advanced adenomas (size ≥10 mm, high-grade dysplasia or ≥25% villous component) cannot optimally distinguish individuals at high risk or low risk of metachronous colorectal cancer (me-CRC), which may result in suboptimal surveillance. Certain DNA copy-number alterations (CNAs) are associated with adenoma-to-carcinoma progression. We aimed to evaluate whether these molecular features can better predict an individual's risk of me-CRC than the morphologic advanced adenoma features.In this nested case-control study, 529 individuals with a single adenoma at first colonoscopy were selected from a Norwegian adenoma cohort. DNA copy-number profiles were determined, by low-coverage whole-genome sequencing. Prevalence of CNAs in advanced and non-advanced adenomas and its association (OR) with me-CRC was assessed. For the latter, cases (with me-CRC) were matched to controls (without me-CRC) on follow-up, age and sex.CNAs associated with adenoma-to-carcinoma progression were observed in 85/267 (32%) of advanced adenomas and in 27/262 (10%) of non-advanced adenomas. me-CRC was statistically significantly associated, also after adjustment for other variables, with age at baseline [OR, 1.14; 95% confidence interval CI), 1.03-1.26; P = 0.012], advanced adenomas (OR, 2.46; 95% CI, 1.50-4.01; P < 0.001) and with the presence of ≥3 DNA copy-number losses (OR, 1.90; 95% CI. 1.02-3.54; P = 0.043).Molecularly-defined high-risk adenomas were associated with me-CRC, but the association of advanced adenoma with me-CRC was stronger.SIGNIFICANCE: Identifying new biomarkers may improve prediction of me-CRC for individuals with adenomas and optimize surveillance intervals to reduce risk of colorectal cancer and reduce oversurveillance of patients with low risk of colorectal cancer. Use of DNA CNAs alone does not improve prediction of me-CRC. Further research to improve risk classification is required.

Published
2023

24. Efficacy and cost-utility of the eHealth application ‘Oncokompas’, supporting patients with incurable cancer in finding optimal palliative care, tailored to their quality of life and personal preferences: a study protocol of a randomized controlled trial

Author

Schuit, Anouk S., Holtmaat, Karen, Hooghiemstra, Nienke, Jansen, Femke, Lissenberg-Witte, Birgit I., Coupé, Veerle M. H., van Linde, Myra E., Becker-Commissaris, Annemarie, Reijneveld, Jaap C., Zijlstra, Josée M., Sommeijer, Dirkje W., Eerenstein, Simone E. J., and Verdonck-de Leeuw, Irma M.

Published
2019
Full Text
View/download PDF

27. Abstract A004: Molecular adenoma features to predict metachronous colorectal cancer risk: A nested-case control study

Author

Jodal, Henriette C., primary, Akwiwu, Eddymurphy U., additional, Leon, Leticia G., additional, Lemmens, Margriet, additional, Delis-van Diemen, Pien, additional, Klotz, Dagmar, additional, de Wit, Meike, additional, Fijneman, Remond, additional, van Leerdam, Monique, additional, Dekker, Evelien, additional, Spaander, Manon C. W., additional, Meijer, Gerrit A., additional, Bretthauer, Michael, additional, Løberg, Magnus, additional, Coupé, Veerle M. H., additional, Kalager, Mette, additional, and Carvalho, Beatriz, additional

Published
2022
Full Text
View/download PDF

30. Cost-Utility of the eHealth Application ‘Oncokompas’, Supporting Incurably Ill Cancer Patients to Self-Manage Their Cancer-Related Symptoms: Results of a Randomized Controlled Trial

Author

Schuit, Anouk S., primary, Holtmaat, Karen, additional, Coupé, Veerle M. H., additional, Eerenstein, Simone E. J., additional, Zijlstra, Josée M., additional, Eeltink, Corien, additional, Becker-Commissaris, Annemarie, additional, van Zuylen, Lia, additional, van Linde, Myra E., additional, Menke-van der Houven van Oordt, C. Willemien, additional, Sommeijer, Dirkje W., additional, Verbeek, Nol, additional, Bosscha, Koop, additional, Nandoe Tewarie, Rishi, additional, Sedee, Robert-Jan, additional, de Bree, Remco, additional, de Graeff, Alexander, additional, de Vos, Filip, additional, Cuijpers, Pim, additional, Verdonck-de Leeuw, Irma M., additional, and Jansen, Femke, additional

Published
2022
Full Text
View/download PDF

31. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) – a phase III single-blind prospective randomized controlled trial

Author

Puijk, Robbert S., Ruarus, Alette H., Vroomen, Laurien G. P. H., van Tilborg, Aukje A. J. M., Scheffer, Hester J., Nielsen, Karin, de Jong, Marcus C., de Vries, Jan J. J., Zonderhuis, Babs M., Eker, Hasan H., Kazemier, Geert, Verheul, Henk, van der Meijs, Bram B., van Dam, Laura, Sorgedrager, Natasha, Coupé, Veerle M. H., van den Tol, Petrousjka M. P., Meijerink, Martijn R., and COLLISION Trial Group

Published
2018
Full Text
View/download PDF

35. sj-pdf-1-mdm-10.1177_0272989X211016307 – Supplemental material for Choosing a Metamodel of a Simulation Model for Uncertainty Quantification

Author

de Carvalho, Tiago M., van Rosmalen, Joost, Wolff, Harold B., Koffijberg, Hendrik, and Coupé, Veerle M. H.

Subjects
111708 Health and Community Services, 111799 Public Health and Health Services not elsewhere classified, 160807 Sociological Methodology and Research Methods, FOS: Health sciences, FOS: Sociology
Abstract

Supplemental material, sj-pdf-1-mdm-10.1177_0272989X211016307 for Choosing a Metamodel of a Simulation Model for Uncertainty Quantification by Tiago M. de Carvalho, Joost van Rosmalen, Harold B. Wolff, Hendrik Koffijberg and Veerle M. H. Coupé in Medical Decision Making

Published
2022
Full Text
View/download PDF

36. Definition of competence standards for optical diagnosis of diminutive colorectal polyps: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement

Author

Houwen, Britt B. S. L., additional, Hassan, Cesare, additional, Coupé, Veerle M. H., additional, Greuter, Marjolein J. E., additional, Hazewinkel, Yark, additional, Vleugels, Jasper L. A., additional, Antonelli, Giulio, additional, Bustamante-Balén, Marco, additional, Coron, Emmanuel, additional, Cortas, George A., additional, Dinis-Ribeiro, Mario, additional, Dobru, Daniela E., additional, East, James E., additional, Iacucci, Marietta, additional, Jover, Rodrigo, additional, Kuvaev, Roman, additional, Neumann, Helmut, additional, Pellisé, Maria, additional, Puig, Ignasi, additional, Rutter, Matthew D., additional, Saunders, Brian, additional, Tate, David J., additional, Mori, Yuichi, additional, Longcroft-Wheaton, Gaius, additional, Bisschops, Raf, additional, and Dekker, Evelien, additional

Published
2021
Full Text
View/download PDF

37. Methodological framework for development of competence standards for optical diagnosis in gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement

Author

Houwen, Britt B. S. L., additional, Hassan, Cesare, additional, Hazewinkel, Yark, additional, Vleugels, Jasper L. A., additional, Dinis-Ribeiro, Mario, additional, Greuter, Marjolein J. E., additional, Coupé, Veerle M. H., additional, Dekker, Evelien, additional, and Bisschops, Raf, additional

Published
2021
Full Text
View/download PDF

38. Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN Initiative

Author

Puijk, Robbert S., primary, Ahmed, Muneeb, additional, Adam, Andreas, additional, Arai, Yasuaki, additional, Arellano, Ronald, additional, de Baère, Thierry, additional, Bale, Reto, additional, Bellera, Carine, additional, Binkert, Christoph A., additional, Brace, Christopher L., additional, Breen, David J., additional, Brountzos, Elias, additional, Callstrom, Matthew R., additional, Carrafiello, Gianpaolo, additional, Chapiro, Julius, additional, de Cobelli, Francesco, additional, Coupé, Veerle M. H., additional, Crocetti, Laura, additional, Denys, Alban, additional, Dupuy, Damian E., additional, Erinjeri, Joseph P., additional, Filippiadis, Dimitris, additional, Gangi, Afshin, additional, Gervais, Debra A., additional, Gillams, Alice R., additional, Greene, Tissy, additional, Guiu, Boris, additional, Helmberger, Thomas, additional, Iezzi, Roberto, additional, Kang, Tae Wook, additional, Kelekis, Alexis, additional, Kim, Hyun S., additional, Kröncke, Thomas, additional, Kwan, Sharon, additional, Lee, Min Woo, additional, Lee, Fred T., additional, Lee, Edward W., additional, Liang, Ping, additional, Lissenberg-Witte, Birgit I., additional, Lu, David S., additional, Madoff, David C., additional, Mauri, Giovanni, additional, Meloni, Maria Franca, additional, Morgan, Robert, additional, Nadolski, Gregory, additional, Narayanan, Govindarajan, additional, Newton, Isabel, additional, Nikolic, Boris, additional, Orsi, Franco, additional, Pereira, Philippe L., additional, Pua, Uei, additional, Rhim, Hyunchul, additional, Ricke, Jens, additional, Rilling, William, additional, Salem, Riad, additional, Scheffer, Hester J., additional, Sofocleous, Constantinos T., additional, Solbiati, Luigi A., additional, Solomon, Stephen B., additional, Soulen, Michael C., additional, Sze, Daniel, additional, Uberoi, Raman, additional, Vogl, Thomas J., additional, Wang, David S., additional, Wood, Bradford J., additional, Goldberg, S. Nahum, additional, and Meijerink, Martijn R., additional

Published
2021
Full Text
View/download PDF

42. Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing

Author

Pasmans, Clémence T. B., primary, Tops, Bastiaan B. J., additional, Steeghs, Elisabeth M. P., additional, Coupé, Veerle M. H., additional, Grünberg, Katrien, additional, de Jong, Eiko K, additional, Schuuring, Ed M. D., additional, Willems, Stefan M., additional, Ligtenberg, Marjolijn J. l., additional, Retèl, Valesca P., additional, van Snellenberg, Hans, additional, de Bruijn, Ewart, additional, Cuppen, Edwin, additional, and Frederix, Geert W. J., additional

Published
2021
Full Text
View/download PDF

43. sj-docx-1-mdm-10.1177_0272989X211016307 – Supplemental material for Choosing a Metamodel of a Simulation Model for Uncertainty Quantification

Author

de Carvalho, Tiago M., van Rosmalen, Joost, Wolff, Harold B., Koffijberg, Hendrik, and Coupé, Veerle M. H.

Subjects
111708 Health and Community Services, 111799 Public Health and Health Services not elsewhere classified, 160807 Sociological Methodology and Research Methods, FOS: Health sciences, FOS: Sociology
Abstract

Supplemental material, sj-docx-1-mdm-10.1177_0272989X211016307 for Choosing a Metamodel of a Simulation Model for Uncertainty Quantification by Tiago M. de Carvalho, Joost van Rosmalen, Harold B. Wolff, Hendrik Koffijberg and Veerle M. H. Coupé in Medical Decision Making

Published
2021
Full Text
View/download PDF

44. sj-pdf-1-tag-10.1177_1756284821995715 – Supplemental material for Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients

Author

Jongeneel, Gabrielle, Greuter, Marjolein J. E., Erning, Felice N. Van, Koopman, Miriam, Vink, Geraldine R., Punt, Cornelis J. A., and Coupé, Veerle M. H.

Subjects
FOS: Clinical medicine, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-pdf-1-tag-10.1177_1756284821995715 for Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients by Gabrielle Jongeneel, Marjolein J. E. Greuter, Felice N. van Erning, Miriam Koopman, Geraldine R. Vink, Cornelis J. A. Punt and Veerle M. H. Coupé in Therapeutic Advances in Gastroenterology

Published
2021
Full Text
View/download PDF

45. Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN Initiative

Author

Puijk, Robbert S. Ahmed, Muneeb Adam, Andreas Arai, Yasuaki Arellano, Ronald de Baère, Thierry Bale, Reto Bellera, Carine Binkert, Christoph A. Brace, Christopher L. Breen, David J. Brountzos, Elias Callstrom, Matthew R. Carrafiello, Gianpaolo Chapiro, Julius de Cobelli, Francesco Coupé, Veerle M. H. Crocetti, Laura Denys, Alban Dupuy, Damian E. Erinjeri, Joseph P. Filippiadis, Dimitris Gangi, Afshin Gervais, Debra A. Gillams, Alice R. Greene, Tissy Guiu, Boris Helmberger, Thomas Iezzi, Roberto Kang, Tae Wook Kelekis, Alexis Kim, Hyun S. Kröncke, Thomas Kwan, Sharon Lee, Min Woo Lee, Fred T. Lee, Edward W. Jr Liang, Ping Lissenberg-Witte, Birgit I. Lu, David S. Madoff, David C. Mauri, Giovanni Meloni, Maria Franca Morgan, Robert Nadolski, Gregory Narayanan, Govindarajan Newton, Isabel Nikolic, Boris Orsi, Franco Pereira, Philippe L. Pua, Uei Rhim, Hyunchul Ricke, Jens Rilling, William Salem, Riad Scheffer, Hester J. Sofocleous, Constantinos T. Solbiati, Luigi A. Solomon, Stephen B. Soulen, Michael C. Sze, Daniel Uberoi, Raman Vogl, Thomas J. Wang, David S. Wood, Bradford J. Goldberg, S. Nahum Meijerink, Martijn R.

Abstract

There is currently no consensus regarding preferred clinical outcome measures following image-guided tumor ablation or clear definitions of oncologic end points. This consensus document proposes standardized definitions for a broad range of oncologic outcome measures with recommendations on how to uniformly document, analyze, and report outcomes. The initiative was coordinated by the Society of Interventional Oncology in collaboration with the Definition for the Assessment of Time-to-Event End Points in Cancer Trials, or DATECAN, group. According to predefined criteria, based on experience with clinical trials, an international panel of 62 experts convened. Recommendations were developed using the validated three-step modified Delphi consensus method. Consensus was reached on when to assess outcomes per patient, per session, or per tumor; on starting and ending time and survival time definitions; and on time-to-event end points. Although no consensus was reached on the preferred classification system to report complications, quality of life, and health economics issues, the panel did agree on using the most recent version of a validated patient-reported outcome questionnaire. This article provides a framework of key opinion leader recommendations with the intent to facilitate a clear interpretation of results and standardize worldwide communication. Widespread adoption will improve reproducibility, allow for accurate comparisons, and avoid misinterpretations in the field of interventional oncology research. Published under a CC BY 4.0 license. Online supplemental material is available for this article. See also the editorial by Liddell in this issue.

Published
2021

46. Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers

Author

MS Medische Oncologie, Cancer, Onderzoek Medische Oncologie, Jongeneel, Gabrielle, Greuter, Marjolein J E, Kunst, Natalia, van Erning, Felice N, Koopman, Miriam, Medema, Jan P, Vermeulen, Louis, Ijzermans, Jan N M, Vink, Geraldine R, Punt, Cornelis J A, Coupé, Veerle M H, MS Medische Oncologie, Cancer, Onderzoek Medische Oncologie, Jongeneel, Gabrielle, Greuter, Marjolein J E, Kunst, Natalia, van Erning, Felice N, Koopman, Miriam, Medema, Jan P, Vermeulen, Louis, Ijzermans, Jan N M, Vink, Geraldine R, Punt, Cornelis J A, and Coupé, Veerle M H

Published
2021

47. Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients

Author

MS Medische Oncologie, Cancer, Onderzoek Medische Oncologie, Epi Kanker Team A, Jongeneel, Gabrielle, Greuter, Marjolein J E, van Erning, Felice N, Koopman, Miriam, Vink, Geraldine R, Punt, Cornelis J A, Coupé, Veerle M H, MS Medische Oncologie, Cancer, Onderzoek Medische Oncologie, Epi Kanker Team A, Jongeneel, Gabrielle, Greuter, Marjolein J E, van Erning, Felice N, Koopman, Miriam, Vink, Geraldine R, Punt, Cornelis J A, and Coupé, Veerle M H

Published
2021

48. Longitudinal effects of adjuvant chemotherapy and related neuropathy on HU in stage II and III colon cancer patients: A prospective cohort study

Author

MS Medische Oncologie, Cancer, Epi Kanker Team A, Onderzoek Medische Oncologie, Jongeneel, Gabrielle, Greuter, Marjolein J E, van Erning, Felice N, Twisk, Jos W R, Koopman, Miriam, Punt, Cornelis J A, Vink, Geraldine R, Coupé, Veerle M H, MS Medische Oncologie, Cancer, Epi Kanker Team A, Onderzoek Medische Oncologie, Jongeneel, Gabrielle, Greuter, Marjolein J E, van Erning, Felice N, Twisk, Jos W R, Koopman, Miriam, Punt, Cornelis J A, Vink, Geraldine R, and Coupé, Veerle M H

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results